文献速递核素与放射性配体治疗

转移性胃肠胰神经内分泌肿瘤患者接受225Ac-DOTATATE靶向α治疗联合卡培他滨的生存结局:基于真实世界场景管理的长期结局研究

Survival Outcomes in Metastatic Gastroenteropancreatic Neuroendocrine Tumor Patients receiving Concomitant 225Ac-DOTATATE–Targeted α-Therapy and Capecitabine: A Real-World-Scenario Management-Based Long-Term Outcome Study.
PubMed 文献 · J Nucl Med · 2022-07-21

该研究纳入91例SSTR表达的晚期转移性胃肠胰神经内分泌肿瘤患者,接受225Ac-DOTATATE靶向α治疗(100-120 kBq/kg体重)联合卡培他滨(2 g/日,每周期第0-14天)作为放射增敏剂。中位随访24个月,中位总生存期未达到,24个月总生存概率为70.8%;中位无进展生存期未达到,24个月无进展生存概率为67.5%。骨转移和225Ac-DOTATATE治疗难治性疾病与较差的总生存期相关,而177Lu-PRRT难治性疾病与较差的无进展生存期相关。

要点

  • 225Ac-DOTATATE联合卡培他滨在晚期GEP-NET中24个月总生存概率70.8%、无进展生存概率67.5%。
  • 骨转移(HR 2.501)和225Ac-DOTATATE治疗难治性疾病(HR 8.781)与较差的总生存期相关。
  • 177Lu-PRRT难治性疾病与较差的无进展生存期相关(HR 14.338)。

核心结论

  • 长期结果显示225Ac-DOTATATE靶向α治疗显示出有前景的结果并改善总生存期,即使在对先前177Lu-DOTATATE治疗难治的患者中也是如此,且不良反应为短暂且可接受。

研究设计与样本

  • 研究纳入91例经68Ga-DOTANOC PET/CT显示中至高SSTR表达的晚期转移性胃肠胰神经内分泌肿瘤成人患者,其中男性54例、女性37例,平均年龄54岁(范围25-75岁)。
  • 所有患者接受225Ac-DOTATATE系统性靶向α治疗,剂量为100-120 kBq/kg体重,并联合卡培他滨作为放射增敏剂,剂量为2 g/日,每周期第0-14天给药。
  • 患者根据既往177Lu-PRRT状态分为三组:既往177Lu-PRRT难治组、既往177Lu-PRRT疾病控制组和177Lu-PRRT初治组。
  • 主要终点为总生存期,次要终点包括无进展生存期、客观肿瘤反应、临床反应和治疗相关毒性评估。

主要发现

  • 91例患者中57例曾接受177Lu-DOTATATE治疗,其中24例疾病控制(PR/SD),33例疾病进展(PD)。
  • 共给予453个225Ac-DOTATATE治疗周期,中位每例4个周期(范围1-10),中位随访24个月(范围5-41个月)。
  • 中位总生存期未达到,24个月总生存概率为70.8%;多因素分析显示骨转移(HR 2.501;95%CI 1.826-5.791;P<0.032)和225Ac-DOTATATE治疗难治性疾病(HR 8.781;95%CI 3.843-20.062;P<0.0001)与较差的总生存期相关。
  • 中位无进展生存期未达到,24个月无进展生存概率为67.5%;多因素分析仅显示177Lu-PRRT难治性疾病与无进展生存期降低显著相关(HR 14.338;95%CI 1.853-97.698;P=0.011)。
  • 79例可评估疾病患者中,2例(2.5%)完全缓解,38例(48%)部分缓解,23例(29%)疾病稳定,16例(20.2%)疾病进展;既往177Lu-PRRT难治组疾病进展患者为11/33(34%),177Lu-PRRT初治患者为4/24(11%),P=0.056。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Although the short-term results of targeted alpha therapy (TAT) with 225Ac-DOTATATE in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have proven effective, none have assessed the long-term outcome results. In this study, we aimed to evaluate the long-term outcome of 225Ac-DOTATATE targeted alpha therapy (TAT) in patients with somatostatin receptor (SSTR)-expressing advanced-stage metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Methods: Patients with 68Ga-DOTANOC PET/CT scans showing moderate-to-high SSTR expression were recruited. Systemic TAT was performed in 91 adults with GEP-NET [54 males, and 37 females] mean age 54 years (y) (range: 25-75y)] using 225Ac-DOTATATE (100-120 kBq/kg body weight). All patients were given capecitabine therapy as a radiosensitizer (dose 2 g/day) from day 0 to 14 of every 225Ac-DOTATATE treatment cycle. Patients were categorized into three groups based on the status of prior 177Lu-PRRT: prior 177Lu-PRRT-refractory-group; prior 177Lu-PRRT-disease-control group; and 177Lu-PRRT naïve group. Primary endpoints were overall survival (OS), and secondary endpoints included progression-free survival (PFS), objective tumour response, clinical response, and the assessment of treatment-related toxicities. Results: Among the 91 patients, 57 underwent prior 177Lu-DOTATATE therapy [24 disease controlled (PR/SD), 33 progressive diseases (PD)]. A total of 453 225Ac-DOTATATE TAT cycles were administered [median four cycles per patient; range 1-10] in a median follow-up duration of 24 months (range 5-41mo). Median OS was not attained with a 24-month overall survival probability of 70.8%. In multivariate analysis, prognostic factors associated with a poor OS included, the presence bone metastases [HR: 2.501; 95% CI: 1.826 - 5.791; P<0.032], and 225Ac-DOTATATE therapy refractory disease [HR: 8.781; 95% CI: 3.843 - 20.062; P<0.0001]. Median PFS was also not reached with a 24-month progression-free survival probability of 67.5%. The multivariate analysis revealed only 177Lu-PRRT refractory disease significantly associated with a reduced PFS. [HR: 14.338; 95% CI: 1.853 - 97.698; P = 0.011]. Two of 79 patients (2.5%) with assessable disease experienced complete response; 38 (48%) had a partial response, 23 (29%) had SD, and 16 (20.2%) had PD. PD was observed in more patients from the prior 177Lu-PRRT-refractory group (11/33; 34%) as compared to 177Lu-PRRT-naïve patients (4/24; 11%), P-0.056. Patients from the prior 177Lu-PRRT-refractory group had the highest risk of poor PFS [HR:13.91; 95% CI: 4.45 - 42.271; P = 0.0009]. A significant clinical benefit was achieved post 225Ac-DOTATATE therapy with minimal treatment-related toxicities. Conclusion: The long-term results reveal 225Ac-DOTATATE TAT has shown promising results and improves overall survival, even in patients refractory to prior 177Lu-DOTATATE treatment, with transient and acceptable adverse effects.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Ballal S, Yadav MP, Tripathi M, et al. Survival Outcomes in Metastatic Gastroenteropancreatic Neuroendocrine Tumor Patients receiving Concomitant 225Ac-DOTATATE–Targeted α-Therapy and Capecitabine: A Real-World-Scenario Management-Based Long-Term Outcome Study. J Nucl Med. 2022. PMID: 35863893. doi:10.2967/jnumed.122.264043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。